Hematological toxicity represents a frequent adverse event after chimeric antigen receptor (CAR) T-cell therapy, and can predispose for severe infectious complications. Determined prior to lymphodepleting chemotherapy (e.g. day -5), the CAR-HEMATOTOX score comprises five markers of hematotoxicity with additional weighting of the baseline platelet count and ferritin levels. The score discriminates between a high (CAR-HEMATOTOX score ≥2) and low (CAR-HEMATOTOX score 0-1) risk for hematotoxicity.
Please note that this score was established and validated only in patients with large B-cell lymphoma receiving Axicabtagene ciloleucel or Tisagenlecleucel in a real-world setting. The model was validated in two independent patient cohorts and discriminated patients with severe neutropenia ≥14 days vs. <14 days (pooled validation: AUC 0.89, sensitivity 89%, specificity 68%).
For details see CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Rejeski et al. Blood (2021) 138 (24): 2499-2513.
In a multi-center follow-up study, the score further identified patients at risk for severe infections and disease progression: The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T for R/R LBCL. Rejeski et al. J Immunother Cancer (2022) May; 10 (5): e004475.
Here you can calculate the CAR-HEMATOTOX score and the resulting risk group (high versus low). By using this calculator, you accept that the GLA does not assume any liability.